OPTIMAL DURATION OF ADJUVANT TRASTUZUMAB THERAPY IN PATIENTS WITH HER2-POSSITIVE EARLY BREAST CANCER: WHETHER THE PROBLEM IS RESOLVED? ArticleZhukova L.G., Ganshina I.P., Khatkova E.I., Tikhomirova T.E., Kondratyeva O.E.Современная онкология. Том 20. 2018. С. 24-28
